Multi-disciplined engineering specialist, WHP announces signing of partnership agreement with ADC Biotechnology (ADC Bio) to construct an anti-cancer drug manufacturing facility in Deeside, North Wales
As the construction partner for ADC Bio, WHP will play a significant role in designing, planning and building the highly-regulated facilities needed to develop the latest generation of anti-cancer blockbuster drugs, antibody drug conjugates (ADCs).
Phase 1 of work commences immediately for a purpose-built, dual-stream facility, which will occupy approximately 60% of ADC Bio’s newly-acquired, 6500m2 space in Deeside.
Planned to be operational in September 2018, the facility will serve clinical and small-scale, commercial production. Further construction activity is planned post January 2019 as ADC Bio continues its expansion and adds more capacity for large-scale clinical, commercial and potential dosage-form production.
Ian Lichfield, CEO of WHP: “Our successful collaborations with biotechnology companies and the wider pharmaceutical industry, creates synergies with ADC Bio and adds value to the construction project. We look forward to a long and fruitful partnership with ADC Bio as the first stage of construction progresses to a second planned phase in 2019 in line with their strategy for expansion.”
Charlie Johnson, CEO of ADC Bio commented: “We are delighted to have forged this agreement with WHP. We specifically selected them as we found that their established reputation and industry recognition for high-quality design and construction of integrated systems and cleanroom technology — specifically within the biotechnology sector — made them the best fit for our needs.”